Washington University

Allergan, Inc.

Steven Teitelbaum

Daved Henry Fremont

Christopher Nelson

Julia T Warren

David V Goeddel

Holger Wesche

Robert D Schreiber

William P Adams, Jr

William P Adams

Carl J DeSelm

Bradley P Bengtson

Methods for constructing efficient inhibitors of target TNF superfamily receptors, single chain target TNF superfamily ligands that inhibit of target TNF superfamily receptors while failing to engage or inhibit non-target TNF superfamily receptors, and methods of their use to treat diseases are provided. Single chain RANKL, TNF, and TRAIL ligands that effectively inhibit their target receptors while failing to inhibit non-target TNF superfamily receptors are also provided.

Mutant tumor necrosis factor receptor superfamily (TNFsfR) ligands and methods of making and using same

Oligomers for TNF superfamily inhibition, methods of making and using

Oligomers for TNF superfamily inhibition

Methods of reducing bone loss and treating degenerative bone diseases such as osteoporosis are disclosed. The methods comprise administration of an agent that inhibits signaling through the IL-17 pathway, such as an antibody or a quinazolinone analogue such as halofuginone.

Methods of treatment of bone degenerative diseases

The present invention provides transgenic non-human mammals and cells having one or more structurally and functionally disrupted NIK alleles. In addition, the present invention provides methods for making such transgenic mammals and cells, and methods for determining the effect of a compound on an animal or cell that lacks NIK function. The present invention also provides methods for identifying compounds useful in the inhibition of osteoclastogenesis in a mammal, for example to treat osteoporosis or other conditions. Also provided are methods of modulating the extent of osteoclastogenesis in a cell or a mammal using NIK modulators.

NIK-knockout mice

Growing community of inventors

St. Louis, MO, United States of America

Steven Teitelbaum